S&P 500   4,600.95 (+1.38%)
DOW   35,283.63 (+2.03%)
QQQ   384.95 (+0.48%)
AAPL   166.13 (+2.65%)
MSFT   323.60 (+0.18%)
FB   315.29 (+2.75%)
GOOGL   2,849.86 (+0.35%)
AMZN   3,451.51 (+1.82%)
TSLA   998.27 (-1.65%)
NVDA   293.21 (-4.47%)
BABA   120.84 (+7.93%)
NIO   32.20 (+0.16%)
CGC   9.97 (-0.20%)
AMD   136.15 (-5.46%)
GE   96.53 (+4.05%)
MU   82.33 (+0.87%)
T   23.48 (+0.09%)
F   19.27 (+0.68%)
DIS   150.15 (+2.69%)
PFE   52.27 (-3.69%)
AMC   28.60 (-1.41%)
ACB   5.88 (+1.03%)
BA   204.97 (+3.26%)
S&P 500   4,600.95 (+1.38%)
DOW   35,283.63 (+2.03%)
QQQ   384.95 (+0.48%)
AAPL   166.13 (+2.65%)
MSFT   323.60 (+0.18%)
FB   315.29 (+2.75%)
GOOGL   2,849.86 (+0.35%)
AMZN   3,451.51 (+1.82%)
TSLA   998.27 (-1.65%)
NVDA   293.21 (-4.47%)
BABA   120.84 (+7.93%)
NIO   32.20 (+0.16%)
CGC   9.97 (-0.20%)
AMD   136.15 (-5.46%)
GE   96.53 (+4.05%)
MU   82.33 (+0.87%)
T   23.48 (+0.09%)
F   19.27 (+0.68%)
DIS   150.15 (+2.69%)
PFE   52.27 (-3.69%)
AMC   28.60 (-1.41%)
ACB   5.88 (+1.03%)
BA   204.97 (+3.26%)
S&P 500   4,600.95 (+1.38%)
DOW   35,283.63 (+2.03%)
QQQ   384.95 (+0.48%)
AAPL   166.13 (+2.65%)
MSFT   323.60 (+0.18%)
FB   315.29 (+2.75%)
GOOGL   2,849.86 (+0.35%)
AMZN   3,451.51 (+1.82%)
TSLA   998.27 (-1.65%)
NVDA   293.21 (-4.47%)
BABA   120.84 (+7.93%)
NIO   32.20 (+0.16%)
CGC   9.97 (-0.20%)
AMD   136.15 (-5.46%)
GE   96.53 (+4.05%)
MU   82.33 (+0.87%)
T   23.48 (+0.09%)
F   19.27 (+0.68%)
DIS   150.15 (+2.69%)
PFE   52.27 (-3.69%)
AMC   28.60 (-1.41%)
ACB   5.88 (+1.03%)
BA   204.97 (+3.26%)
S&P 500   4,600.95 (+1.38%)
DOW   35,283.63 (+2.03%)
QQQ   384.95 (+0.48%)
AAPL   166.13 (+2.65%)
MSFT   323.60 (+0.18%)
FB   315.29 (+2.75%)
GOOGL   2,849.86 (+0.35%)
AMZN   3,451.51 (+1.82%)
TSLA   998.27 (-1.65%)
NVDA   293.21 (-4.47%)
BABA   120.84 (+7.93%)
NIO   32.20 (+0.16%)
CGC   9.97 (-0.20%)
AMD   136.15 (-5.46%)
GE   96.53 (+4.05%)
MU   82.33 (+0.87%)
T   23.48 (+0.09%)
F   19.27 (+0.68%)
DIS   150.15 (+2.69%)
PFE   52.27 (-3.69%)
AMC   28.60 (-1.41%)
ACB   5.88 (+1.03%)
BA   204.97 (+3.26%)
NASDAQ:FWBI

First Wave BioPharma Stock Forecast, Price & News

$1.37
-0.06 (-4.20%)
(As of 12/6/2021 12:38 PM ET)
Add
Compare
Today's Range
$1.28
$1.42
50-Day Range
$1.43
$3.40
52-Week Range
$1.35
$26.30
Volume
22,333 shs
Average Volume
905,666 shs
Market Capitalization
$17.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.73
30 days | 90 days | 365 days | Advanced Chart
Receive FWBI News and Ratings via Email

Sign-up to receive the latest news and ratings for First Wave BioPharma and its competitors with MarketBeat's FREE daily newsletter.


First Wave BioPharma logo

About First Wave BioPharma

First Wave Biopharma, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The firm involves in therapeutic development pipeline populated with multiple clinical stage programs built around its proprietary technologies, such as Niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its programs include FW-UP, FW-UC, FW-CD,FW-COV, FW-ICI-AC, MS1819, COVID-19 GI infections, and FW-EPI. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.

Headlines

First Wave Restructures Merger Consideration Payment Terms
November 16, 2021 |  finance.yahoo.com
First Wave BioPharma, Inc. Common Stock (FWBI)
November 8, 2021 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FWBI
Fax
N/A
Employees
12
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
($0.56) per share

Profitability

Net Income
$-32.67 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
11,786,000
Market Cap
$17.07 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/14/2021
Today
12/06/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/30/2022

MarketRank

Overall MarketRank

1.48 out of 5 stars

Medical Sector

1083rd out of 1,388 stocks

Pharmaceutical Preparations Industry

514th out of 670 stocks

Analyst Opinion: 3.5Community Rank: 1.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












First Wave BioPharma (NASDAQ:FWBI) Frequently Asked Questions

Is First Wave BioPharma a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for First Wave BioPharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" First Wave BioPharma stock.
View analyst ratings for First Wave BioPharma
or view top-rated stocks.

When is First Wave BioPharma's next earnings date?

First Wave BioPharma is scheduled to release its next quarterly earnings announcement on Wednesday, March 30th 2022.
View our earnings forecast for First Wave BioPharma
.

How were First Wave BioPharma's earnings last quarter?

First Wave BioPharma Inc (NASDAQ:FWBI) posted its quarterly earnings data on Sunday, November, 14th. The company reported ($3.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.79) by $2.48.
View First Wave BioPharma's earnings history
.

What price target have analysts set for FWBI?

1 brokerages have issued 12 month price objectives for First Wave BioPharma's shares. Their forecasts range from $8.00 to $8.00. On average, they expect First Wave BioPharma's stock price to reach $8.00 in the next year. This suggests a possible upside of 483.9% from the stock's current price.
View analysts' price targets for First Wave BioPharma
or view top-rated stocks among Wall Street analysts.

Who are First Wave BioPharma's key executives?

First Wave BioPharma's management team includes the following people:
  • James E. Sapirstein, Chairman, President & Chief Executive Officer
  • Daniel H. Schneiderman, Chief Financial Officer
  • James E. Pennington, Chief Medical Officer
  • Loreal McDonald, General Counsel

What is First Wave BioPharma's stock symbol?

First Wave BioPharma trades on the NASDAQ under the ticker symbol "FWBI."

Who are First Wave BioPharma's major shareholders?

First Wave BioPharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (0.93%), Geode Capital Management LLC (0.51%), Parsons Capital Management Inc. RI (0.18%) and BlackRock Inc. (0.12%).

Which major investors are buying First Wave BioPharma stock?

FWBI stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Geode Capital Management LLC, Parsons Capital Management Inc. RI, and BlackRock Inc..

How do I buy shares of First Wave BioPharma?

Shares of FWBI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is First Wave BioPharma's stock price today?

One share of FWBI stock can currently be purchased for approximately $1.37.

How much money does First Wave BioPharma make?

First Wave BioPharma has a market capitalization of $17.07 million. The company earns $-32.67 million in net income (profit) each year or ($9.37) on an earnings per share basis.

How many employees does First Wave BioPharma have?

First Wave BioPharma employs 12 workers across the globe.

What is First Wave BioPharma's official website?

The official website for First Wave BioPharma is www.azurrx.com.

Where are First Wave BioPharma's headquarters?

First Wave BioPharma is headquartered at 760 Parkside Ave Ste 304, Brooklyn, New York 11226-1784.

How can I contact First Wave BioPharma?

First Wave BioPharma's mailing address is 760 Parkside Ave Ste 304, Brooklyn, New York 11226-1784. The company can be reached via phone at (561) 589-7020 or via email at [email protected].


This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.